Dr. Chris Emig, Founder and Chief Executive of Augmenta Bioworks The B-cell receptor repertoire can now be queried by next generation sequencing (NGS) at a scale that enables the rapid collection of millions of antibody sequences from any given individual. The resulting pool of rationally selected antibodies gives researchers access to a comprehensive database of antigen-specific binders and increases the chances of identifying the best antibody sequences. The growing volume of such NGS antibody repositories opens opportunities for alternative methods of therapeutic antibody discovery. Augmenta Bioworks, a biotechnology company headed by Chris Emig, PhD, Co-Founder and Chief Executive Officer, is actively engaged in the discovery of new therapeutics by harnessing the most powerful force in the fight against disease—natural human immunity. This group has developed a novel strategy called the DeepGrid™ platform, which combines single-cell sorting with RNA sequencing to pinpoint the protective immune response of individuals and translate these discoveries into therapies. Dr. Emig explains, "We’re currently working on immune profiling and antibody discovery. Augmenta provides deep insights into human immune repertoires and a technical suite for discovering antibodies of high therapeutic potential. We work with a range of scientists, from academics seeking better insights into human immunity...

Learn how scientists have built a scalable approach using CRISPR-Cas9 and the SH800 cell sorter from Sony to research restoring vision in people with optic neuropathies.

A study of porcine iPS cells in an SLA-matched setting is a possible robust model for transplantation of human iPS cells in an HLA-matched setting. The Sony SH800 was used to perform the NK mediated cytotoxicity assay.

Learn how the Sony SH800S cell sorter supports gene expression profiling to purify phenotypically similar cell populations in bulk.

Researchers used spectral flow cytometry and fluorescent proteins to capture both movement and interactions of immune cells in live mice.

Placing several fluorescent proteins together in a flow cytometry panel offers greater power and capability for experiments. However, handling autofluorescent signal with fluorescent proteins is out of reach for conventional flow cytometetry users. Sony spectral flow cytometry analyzers enable researchers to harness up to five near infra-red fluorescent proteins in a single experiment. Moreover, spectral technology lets users accurately identify autofluorescence, and eliminate it if needed.

Researchers are isolating the Candidatus Erwinia dacicola bacteria from the guts of olive flies on a Sony SH800S and amplifiying Genomic DNA to construct a library for sequencing.

Join us for a free webinar on Spectral Flow and FCS Express 6 which provides native support for Sony spectral data files. See how spectral flow cytometry delivers better data and simplifies panel design. In addition we’ll show how seamless integration between FCS Express and Sony spectral flow cytometry analyzers allows you to move quickly from acquisition to expanded data visualization with spectral overlays, tSNE, Spade, and plate based heat maps.

Listen to Dr. Feng Zhang who was first to adapt CRISPR-Cas9 for genome editing on eukaryotic cells explain CRISPR:

Pluripotent stem cells (PSCs) offer an unprecedented opportunity for both disease modeling and personalized medicine. In particular, PSC derived cardiomyocytes (CM) mature into adult cardiomyocytes when transplanted into neonatal rat hearts allowing iPSC modeling of cardiomyopathy. A recent published study by Kwong et al 1 shows the successful isolation of cardiac progenitor cells (CPCs) from mouse embryonic stem cells. To achieve this, a mESC line expressing Isl1-Cre; Rosa-RFP; aMHC-GFP was generated. The expression of Rosa-RFP allowed tracking of CPCs destined to mature into CM. RFP+ CPCs were sorted using the Sony SH800 cell sorter using the 130um microfluidics sorting chip.